


# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2013 October 15; 5(10): 195-197



## Editorial Board

2011-2015

The *World Journal of Gastrointestinal Oncology* Editorial Board consists of 428 members, representing a team of worldwide experts in gastrointestinal oncology. They are from 40 countries, including Argentina (2), Australia (10), Belgium (5), Brazil (2), Canada (4), Chile (2), China (56), Czech Republic (1), Denmark (1), Finland (3), France (7), Germany (24), Greece (13), Hungary (2), India (9), Iran (2), Ireland (2), Israel (4), Italy (41), Japan (47), Kuwait (2), Mexico (1), Netherlands (7), New Zealand (2), Norway (1), Poland (3), Portugal (5), Romania (1), Saudi Arabia (1), Serbia (2), Singapore (4), South Korea (27), Spain (10), Sweden (5), Switzerland (2), Syria (1), Thailand (1), Turkey (6), United Kingdom (15), and United States (95).

### EDITORS-IN-CHIEF

Wasaburo Koizumi, *Kanagawa*  
Hsin-Chen Lee, *Taipei*  
Dimitrios H Roukos, *Ioannina*

### STRATEGY ASSOCIATE

#### EDITORS-IN-CHIEF

Jian-Yuan Chai, *Long Beach*  
Antonio Macrì, *Messina*  
Markus Kurt Menges, *Schwaebisch Hall*

### GUEST EDITORIAL BOARD MEMBERS

Da-Tian Bau, *Taichung*  
Jui-I Chao, *Hsinchu*  
Chiao-Yun Chen, *Kaohsiung*  
Joanne Jeou-Yuan Chen, *Taipei*  
Shih-Hwa Chiou, *Taipei*  
Tzeon-Jye Chiou, *Taipei*  
Jing-Gung Chung, *Taichung*  
Yih-Gang Goan, *Kaohsiung*  
Li-Sung Hsu, *Taichung*  
Tsann-Long Hwang, *Taipei*  
Long-Bin Jeng, *Taichung*  
Kwang-Huei Lin, *Taoyuan*  
Joseph T Tseng, *Tainan*  
Jaw Yuan Wang, *Kaohsiung*  
Tzu-Chen Yen, *Taoyuan*

### MEMBERS OF THE EDITORIAL BOARD



#### Argentina

María Eugenia Pasqualini, *Córdoba*  
Lydia Inés Puricelli, *Buenos Aires*



#### Australia

Ned Abraham, *NSW*

Stephen John Clarke, *NSW*  
Michael Gnant, *Vienna*  
Michael McGuckin, *South Brisbane*  
Muhammed Ashraf Memon, *Queensland*  
Liang Qiao, *NSW*  
Rodney John Scott, *NSW*  
Joanne Patricia Young, *Herston Q*  
Xue-Qin Yu, *NSW*  
Xu Dong Zhang, *NSW*



#### Belgium

Wim Peter Ceelen, *Ghent*  
Van Cutsem Eric, *Leuven*  
Suriano Gianpaolo, *Brussels*  
Xavier Sagaert, *Leuven*  
Jan B Vermorken, *Edegem*



#### Brazil

Raul Angelo Balbinotti, *Caxias do Sul*  
Sonia Maria Olinari, *Colombo*



#### Canada

Alan Graham Casson, *Saskatoon*  
Hans Tse-Kan Chung, *Toronto*  
Rami Kotb, *Sherbrooke*  
Sai Yi Pan, *Ottawa*



#### Chile

Alejandro Hernan Corvalan, *Santiago*  
Juan Carlos Roa, *Temuco*



#### China

Dong Chang, *Beijing*  
George G Chen, *Hong Kong*  
Yong-Chang Chen, *Zhenjiang*  
Chi-Hin Cho, *Hong Kong*  
Ming-Xu Da, *Lanzhou*  
Xiang-Wu Ding, *Xiangfan*  
Yan-Qing Ding, *Guangzhou*  
Bi Feng, *Chengdu*  
Jin Gu, *Beijing*  
Qin-Long Gu, *Shanghai*  
Hai-Tao Guan, *Xi'an*  
Chun-Yi Hao, *Beijing*  
Yu-Tong He, *Shijiazhuang*  
Jian-Kun Hu, *Chengdu*  
Huang-Xian Ju, *Nanjing*  
Wai-Lun Law, *Hong Kong*  
Ming-Yu Li, *Lanzhou*  
Shao Li, *Beijing*  
Ka-Ho Lok, *Hong Kong*  
Maria Li Lung, *Hong Kong*  
Simon Ng, *Hong Kong*  
Wei-Hao Sun, *Nanjing*  
Qian Tao, *Hong Kong*  
Bin Wang, *Nanjing*  
Chun-You Wang, *Wuhan*  
Kai-Juan Wang, *Zhengzhou*  
Wei-Hong Wang, *Beijing*  
Ya-Ping Wang, *Nanjing*  
Ai-Wen Wu, *Beijing*  
Zhao-Lin Xia, *Shanghai*  
Xue-Yuan Xiao, *Beijing*  
Dong Xie, *Shanghai*  
Guo-Qiang Xu, *Hangzhou*  
Yi-Zhuang Xu, *Beijing*  
Winnie Yeo, *Hong Kong*  
Ying-Yan Yu, *Shanghai*



Siu Tsan Yuen, *Hong Kong*  
 Wei-Hui Zhang, *Harbin*  
 Li Zhou, *Beijing*  
 Yong-Ning Zhou, *Lanzhou*



#### Czech Republic

Ondrej Slaby, *Brno*



#### Denmark

Hans Jørgen Nielsen, *Hvidovre*



#### Finland

Riyad Bendardaf, *Turku*  
 Pentti Ilmari Sipponen, *Espoo*  
 Markku Voutilainen, *Jyväskylä*



#### France

Bouvier Anne-Marie, *Cedex*  
 Stéphane Benoist, *Boulogne*  
 Ouaisi Mehdi, *Marseille*  
 Jean-François Rey, *Jean-François Rey*  
 Karem Slim, *Clermont-Ferrand*  
 David Tougeron, *Poitiers*  
 Isabelle Van Seuning, *Lille*



#### Germany

Hajri Amor, *Freiburg*  
 Han-Xiang An, *Marburg*  
 Karl-Friedrich Becker, *München*  
 Stefan Boeck, *Munich*  
 Dietrich Doll, *Marburg*  
 Joachim Drevs, *Freiburg*  
 Volker Ellenrieder, *Marburg*  
 Ines Gütgemann, *Bonn*  
 Jakob Robert Izbicki, *Hamburg*  
 Gisela Keller, *München*  
 Jörg H Kleeff, *Munich*  
 Axel Kleespies, *Munich*  
 Hans-Joachim Meyer, *Solingen*  
 Lars Mueller, *Kiel*  
 Martina Müller-Schilling, *Heidelberg*  
 Joachim Pfannschmidt, *Heidelberg*  
 Marc André Reymond, *Bielefeld*  
 Robert Rosenberg, *München*  
 Ralph Schneider, *Marburg*  
 Helmut K Seitz, *Heidelberg*  
 Nikolas Hendrik Stoecklein, *Düsseldorf*  
 Oliver Stoeltzing, *Mainz*  
 Ludwig G Strauss, *Heidelberg*



#### Greece

Ekaterini Chatzaki, *Alexandroupolis*  
 Elco de Bree, *Heraklion*  
 Maria Gazouli, *Athens*  
 Vassilis Georgoulas, *Heraklion*  
 John Griniatsos, *Athens*  
 Ioannis D Kanellos, *Thessaloniki*  
 Vaios Karanikas, *Larissa*  
 Georgios Koukourakis, *Athens*

Michael I Koukourakis, *Alexandroupolis*  
 Gregory Kouraklis, *Athens*  
 Kostas Syrigos, *Athens*  
 Ioannis A Voutsadakis, *Larissa*



#### Hungary

László Herszényi, *Budapest*  
 Zsuzsa Schaff, *Budapest*



#### India

Uday Chand Ghoshal, *Lucknow*  
 Ruchika Gupta, *New Delhi*  
 Kalpesh Jani, *Vadodara*  
 Ashwani Koul, *Chandigarh*  
 Balraj Mittal, *Lucknow*  
 Rama Devi Mittal, *Lucknow*  
 Susanta Roychoudhury, *Kolkata*  
 Yogeshwer Shukla, *Lucknow*  
 Imtiaz Ahmed Wani, *Kashmir*



#### Iran

Reza Malekzadeh, *Tehran*  
 Mohamad Amin Pourhoseingholi, *Tehran*



#### Ireland

Aileen Maria Houston, *Cork*  
 Colm Ó'Moráin, *Dublin*



#### Israel

Nadir Arber, *Tel Aviv*  
 Eytan Domany, *Rehovot*  
 Dan David Herskho, *Haifa*  
 Yaron Niv, *Patch Tikva*



#### Italy

Massimo Aglietta, *Turin*  
 Domenico Alvaro, *Rome*  
 Azzariti Amalia, *Bari*  
 Marco Braga, *Milan*  
 Federico Cappuzzo, *Rozzano*  
 Lorenzo Capussotti, *Torino*  
 Fabio Carboni, *Rome*  
 Vincenzo Cardinale, *Rome*  
 Luigi Cavanna, *Piacenza*  
 Massimo Colombo, *Milan*  
 Valli De Re, *Pordenone*  
 Ferdinando De Vita, *Naples*  
 Riccardo Dolcetti, *Aviano*  
 Pier Francesco Ferrucci, *Milano*  
 Francesco Fiorica, *Ferrara*  
 Gennaro Galizia, *Naples*  
 Silvano Gallus, *Milano*  
 Milena Gusella, *Trecenta*  
 Carlo La Vecchia, *Milano*  
 Roberto Francesco Labianca, *Bergamo*  
 Massimo Libra, *Catania*  
 Roberto Manfredi, *Bologna*  
 Gabriele Masselli, *Viale del Policlinico*  
 Simone Mocellin, *Padova*

Gianni Mura, *Arezzo*  
 Gerardo Nardone, *Napoli*  
 Gabriella Nesi, *Florence*  
 Francesco Perri, *San Giovanni Rotondo*  
 Francesco Recchia, *Avezzano*  
 Vittorio Ricci, *Pavia*  
 Fabrizio Romano, *Monza*  
 Antonio Russo, *Palermo*  
 Daniele Santini, *Rome*  
 Claudio Sorio, *Verona*  
 Cosimo Sperti, *Padova*  
 Gianni Testino, *Genova*  
 Giuseppe Tonini, *Rome*  
 Bruno Vincenzi, *Rome*  
 Zoli Wainer, *Forlì*  
 Angelo Zullo, *Rome*



#### Japan

Suminori Akiba, *Kagoshima*  
 Keishiro Aoyagi, *Kurume*  
 Narikazu Boku, *Shizuoka*  
 Yataro Daigo, *Tokyo*  
 Itaru Endo, *Yokohama*  
 Mitsuhiro Fujishiro, *Tokyo*  
 Osamu Handa, *Kyoto*  
 Kenji Hibi, *Yokohama*  
 Asahi Hishida, *Nagoya*  
 Eiso Hiyama, *Hiroshima*  
 Atsushi Imagawa, *Okayama*  
 Johji Inazawa, *Tokyo*  
 Terumi Kamisawa, *Tokyo*  
 Tatsuo Kanda, *Niigata*  
 Masaru Katoh, *Tokyo*  
 Takayoshi Kiba, *Hyogo*  
 Hajime Kubo, *Kyoto*  
 Hiroki Kuniyasu, *Kashiwara*  
 Yukinori Kurokawa, *Osaka*  
 Chihaya Maesawa, *Morioka*  
 Yoshinori Marunaka, *Kyoto*  
 Osam Mazda, *Kyoto*  
 Shinichi Miyagawa, *Matsumoto*  
 Eiji Miyoshi, *Suita*  
 Toshiyuki Nakayama, *Nagasaki*  
 Masahiko Nishiyama, *Saitama*  
 Koji Oba, *Kyoto*  
 Masayuki Ohtsuka, *Chiba*  
 Masao Seto, *Aichi*  
 Tomoyuki Shibata, *Aichi*  
 Mitsugi Shimoda, *Tochigi*  
 Haruhiko Sugimura, *Hamamatsu*  
 Tomomitsu Tahara, *Aichi*  
 Shinji Takai, *Osaka*  
 Satoru Takayama, *Nagoya*  
 Akio Tomoda, *Tokyo*  
 Akihiko Tsuchida, *Tokyo*  
 Yasuo Tsuchiya, *Niigata*  
 Takuya Watanabe, *Niigata*  
 Toshiaki Watanabe, *Tokyo*  
 Yo-ichi Yamashita, *Hiroshima*  
 Hiroki Yamaue, *Wakayama*  
 Hiroshi Yasuda, *Kanagawa*  
 Hiroshi Yokomizo, *Kumamoto*  
 Yutaka Yonemura, *Osaka*  
 Reigetsu Yoshikawa, *Hyogo*



#### Kuwait

Fahd Al-Mulla, *Safat*

Salem Alshemmari, *Safat*



#### **Mexico**

Oscar G Arrieta Rodriguez, *Mexico City*



#### **Netherlands**

Jan Paul De Boer, *Amsterdam*

Bloemena Elisabeth, *Bloemena Elisabeth*

Peter JK Kuppen, *Leiden*

Gerrit Albert Meijer, *Amsterdam*

Anyan N Milne, *Utrecht*

Godefridus J Peters, *Amsterdam*

Cornelis FM Sier, *Leiden*



#### **New Zealand**

Lynnette Robin Ferguson, *Auckland*

Jonathan Barnes Koea, *Auckland*



#### **Norway**

Kjetil Søreide, *Stavanger*



#### **Poland**

Andrzej Szkaradkiewicz, *Poznan*

Michal Tenderenda, *Polskiego*

Jerzy Wydmański, *Gliwice*



#### **Portugal**

Maria de Fátima Moutinho Gärtner, *Porto*

Celso Albuquerque Reis, *Porto*

Lucio Lara Santos, *Porto*

Maria Raquel Campos Seruca, *Porto*

Manuel António Rodrigues Teixeira, *Porto*



#### **Romania**

Marius Raica, *Timisoara*



#### **Saudi Arabia**

Ragab Hani Donkol, *Abha*



#### **Serbia**

Milos M Bjelovic, *Belgrade*

Goran Zoran Stanojevic, *Nis*



#### **Singapore**

Peh Yean Cheah, *Singapore*

Si-Shen Feng, *Singapore*

Zhi-Wei Huang, *Singapore*

Qi Zeng, *Singapore*



#### **South Korea**

Seungmin Bang, *Seoul*

Daeho Cho, *Seoul*

Byung Ihn Choi, *Seoul*

Hyun Cheol Chung, *Seoul*

Sang-Uk Han, *Suwon*

Jun-Hyeog Jang, *Incheon*

Seong Woo Jeon, *Daegu*

Dae Hwan Kang, *Mulgeum-Gigu*

Gyeong Hoon Kang, *Seoul*

Dong Yi Kim, *Gwangju*

Jae J Kim, *Seoul*

Jin Cheon Kim, *Seoul*

Jong Gwang Kim, *Daegu*

Min Chan Kim, *Busan*

Samyong Kim, *Daejeon*

Inchul Lee, *Seoul*

Jung Weon Lee, *Seoul*

Kyu Taek Lee, *Seoul*

Kyung Hee Lee, *Daegu*

Na Gyong Lee, *Seoul*

Suk Kyeong Lee, *Seoul*

Jong-Baeck Lim, *Seoul*

Young Joo Min, *Ulsan*

Sung-Soo Park, *Seoul*

Young Kee Shin, *Seoul*

Hee Jung Son, *Seoul*

Si Young Song, *Seoul*



#### **Spain**

Manuel Benito, *Madrid*

Ignacio Casal, *Madrid*

Antoni Castells, *Barcelona*

Jose JG Marin, *Salamanca*

Joan Maurel, *Barcelona*

Emma Folch Puy, *Barcelona*

Jose Manuel Ramia, *Guadalajara*

Margarita Sanchez-Beato, *Madrid*

Laura Valle, *Barcelona*

Jesus Vioque, *San Juan*



#### **Sweden**

Nils Albiin, *Stockholm*

Samuel Lundin, *Göteborg*

Haile Mahteme, *Uppsala*

Richard Palmqvist, *Umea*

Ning Xu, *Lund*



#### **Switzerland**

Paul M Schneider, *Zurich*

Luigi Tornillo, *Basel*



#### **Syria**

Zuhir Alshehabi, *Lattakia*



#### **Thailand**

Sopit Wongkham, *Khon Kaen*



#### **Turkey**

Uğur Coşkun, *Ankara*

Sukru Mehmet Erturk, *Istanbul*

Vedat Goral, *Diyarbakir*

Yavuz Selim Sari, *Istanbul*

Mesut Tez, *Ankara*

Murat H Yener, *Istanbul*



#### **United Kingdom**

Shrikant Anant, *Oklahoma City*

Runjan Chetty, *Scotland*

Chris Deans, *Edinburgh*

Dipok Kumar Dhar, *London*

Thomas Ronald Jeffry Evans, *Glasgow*

Giuseppe Garcea, *Leicester*

Oleg Gerasimenko, *Liverpool*

Neena Kalia, *Birmingham*

Anthony Maraveyas, *East Yorkshire*

Andrew Maw, *North Wales*

Kymberley Thorne, *Swansea*

Chris Tselepis, *Birmingham*

Nicholas Francis Scot Watson, *Nottingham*

Ling-Sen Wong, *Coventry*

Lu-Gang Yu, *Liverpool*



#### **United States**

Mohammad Reza Abbaszadegan, *Phoenix*

Gianfranco Alpini, *Temple*

Seung Joon Baek, *Knoxville*

Jamie S Barkin, *Miami Beach*

Carol Bernstein, *Arizona*

Paolo Boffetta, *New York*

Kimberly Maureen Brown, *Kansas City*

De-Liang Cao, *Springfield*

Weibiao Cao, *Providence*

Chris N Conteas, *Los Angeles*

Pelayo Correa, *Nashville*

Joseph John Cullen, *JCP*

James Campbell Cusack, *Boston*

Ananya Das, *Scottsdale*

Juan Dominguez-Bendala, *Miami*

Wafik S El-Deiry, *Philadelphia*

Laura Elnitski, *Rockville*

Guy Douglas Eslick, *Boston*

Thomas Joseph Fahey III, *New York*

James W Freeman, *San Antonio*

Bruce Joseph Giantonio, *Philadelphia*

Ajay Goel, *Dallas*

Karen Gould, *Omaha*

Nagana Gowda A Gowda, *West Lafayette*

Stephen Randolph Grobmyer, *Florida*

Young S Hahn, *Charlottesville*

John W Harmon, *Maryland*

Paul J Higgins, *New York*

Steven Norbit Hochwald, *Gainesville*

Jason L Hornick, *Boston*

Qin Huang, *Duarte*

Su-Yun Huang, *Houston*

Jamal A Ibdah, *Columbia*

Yihong Jiang-Cao Kaufmann, *Little Rock*

Temitope Olubunmilayo Keku, *Chapel Hill*

Saeed Khan, *Silver Spring*

Vijay Pranjivan Khatri, *Sacramento*

Peter Sean Kozuch, *New York*  
 Sunil Krishnan, *Houston*  
 Robert R Langley, *Houston*  
 Feng-Zhi Li, *New York*  
 Otto Schiueh-Tzang Lin, *Seattle*  
 Ke-Bin Liu, *Augusta*  
 Rui-Hai Liu, *Ithaca*  
 Xiang-Dong Liu, *Wilmington*  
 Deryk Thomas Loo, *South San Francisco*  
 Andrew M Lowy, *La Jolla*  
 Bo Lu, *Nashville*  
 David M Lubman, *Ann Arbor*  
 James David Luketich, *Pittsburgh*  
 Ju-Hua Luo, *Morgantown*  
 Henry T Lynch, *Omaha*  
 Shelli R Mcalpine, *San Diego*  
 Ellen Darcy McPhail, *Rochester*  
 Anil Mishra, *Cincinnati*  
 Priyabrata Mukherjee, *Rochester*

Steffan Todd Nawrocki, *San Antonio*  
 Kevin Tri Nguyen, *Pittsburgh*  
 Shuji Ogino, *Boston*  
 Macaulay Onuigbo, *Eau Claire*  
 Jong Park, *Tampa*  
 Philip Agop Philip, *Detriot*  
 Blase N Polite, *Chicago*  
 James Andrew Radosevich, *Chicago*  
 Jasti S Rao, *Peoria*  
 Srinevas Kadumpalli Reddy, *Durham*  
 Raffaniello Robert, *New York*  
 Stephen H Safe, *College Station*  
 Muhammad Wasif Saif, *New Haven*  
 Prateek Sharma, *Kansas City*  
 Eric Tatsuo Shinohara, *Philadelphia*  
 Liviu Andrei Sicinski, *Nashville*  
 William Small Jr, *Chicago*  
 Sanjay K Srivastava, *Amarillo*  
 Gloria H Su, *New York*

Sujha Subramanian, *Waltham*  
 Mitsushige Sugimoto, *Texas*  
 David W Townsend, *Knoxville*  
 Asad Umar, *Rockville*  
 Ji-Ping Wang, *Buffalo*  
 Zheng-He Wang, *Cleveland*  
 Michael J Wargovich, *Charleston*  
 Neal W Wilkinson, *Iowa City*  
 Siu-Fun Wong, *Pomona*  
 Shen-Hong Wu, *New York*  
 Jing-Wu Xie, *Indianapolis*  
 Ke-Ping Xie, *Houston*  
 Hao-Dong Xu, *Rochester*  
 Xiao-Chun Xu, *Houston*  
 Gary Y Yang, *New York*  
 Wan-Cai Yang, *Chicago*  
 Zeng-Quan Yang, *Detroit*  
 Zuo-Feng Zhang, *South Los Angeles*  
 Andrew X Zhu, *Boston*



**CASE REPORT**

- 195** Obstructive jaundice due to a rare periampullary tumor  
*Sathyamurthy A, Choudhary A, Ng D, Okponobi S, Diaz-Arias A, Grewal A,  
Hammoud GM*

## Contents

*World Journal of Gastrointestinal Oncology*  
Volume 5 Number 10 October 15, 2013

### APPENDIX

I-V Instructions to authors

### ABOUT COVER

Sathyamurthy A, Choudhary A, Ng D, Okponobi S, Diaz-Arias A, Grewal A, Hammoud GM. Obstructive jaundice due to a rare periampullary tumor. *World J Gastrointest Oncol* 2013; 5(10): 195-197  
<http://www.wjgnet.com/1948-5204/full/v5/i10/195.htm>  
<http://dx.doi.org/10.4251/wjgo.v5.i10.195>

### AIM AND SCOPE

*World Journal of Gastrointestinal Oncology* (*World J Gastrointest Oncol*, *WJGO*, online ISSN 1948-5204, DOI: 10.4251) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJGO* covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, and therapy of benign and malignant tumors of the digestive tract. The current columns of *WJGO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

### INDEXING/ABSTRACTING

*World Journal of Gastrointestinal Oncology* is now indexed in PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

### FLYLEAF

I-IV Editorial Board

### EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xin-Xin Che*  
Responsible Electronic Editor: *Ya-Jing Lu*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ya-Juan Ma*

#### NAME OF JOURNAL

*World Journal of Gastrointestinal Oncology*

#### ISSN

ISSN 1948-5204 (online)

#### LAUNCH DATE

October 15, 2009

#### FREQUENCY

Monthly

#### EDITORS-IN-CHIEF

**Wasaburo Koizumi, MD, PhD, Professor, Chairman**, Department of Gastroenterology, Gastrointestinal Oncology, School of Medicine, Kitasato University, 2-1-1 Asamizodai Minamiku Sagamihara Kanagawa 252-0380, Japan

**Hsin-Chen Lee, PhD, Professor**, Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan

**Dimitrios H Roukos, MD, PhD, Professor, Person-**

alized Cancer Genomic Medicine, Human Cancer Biobank Center, Ioannina University, Metabatiko Ktirio Panepistimiou Ioanninon, Office 229, Ioannina, TK 45110, Greece

#### EDITORIAL OFFICE

Jin-Lei Wang, Director  
Xiu-Xia Song, Vice Director  
*World Journal of Gastrointestinal Oncology*  
Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: [wjgo@wjgnet.com](mailto:wjgo@wjgnet.com)  
<http://www.wjgnet.com>

#### PUBLISHER

Baishideng Publishing Group Co., Limited  
Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road, Wanchai, Hong Kong, China  
Fax: +852-65557188  
Telephone: +852-31779906  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

#### PUBLICATION DATE

October 15, 2013

#### COPYRIGHT

© 2013 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

#### SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

#### INSTRUCTIONS TO AUTHORS

Full instructions are available online at [http://www.wjgnet.com/2222-0682/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2222-0682/g_info_20100722180909.htm).

#### ONLINE SUBMISSION

<http://www.wjgnet.com/esps/>

## Obstructive jaundice due to a rare periampullary tumor

Anjana Sathyamurthy, Abhishek Choudhary, Dennis Ng, Shuaib Okponobi, Alberto Diaz-Arias, Ajitinder Grewal, Ghassan M Hammoud

Anjana Sathyamurthy, Abhishek Choudhary, Dennis Ng, Ajitinder Grewal, Ghassan M Hammoud, Division of Gastroenterology and Hepatology, University of Missouri-Columbia, Columbia, MI 65212, United States

Shuaib Okponobi, Alberto Diaz-Arias, Department of Pathology and Anatomical Sciences, University of Missouri Health Sciences Center, Columbia, MI 65212, United States

**Author contributions:** Sathyamurthy A wrote the manuscript; Choudhary A, Ng D and Grewal A were involved in reviewing the literature; Okponobi S and Diaz-Arias A provided pathology slides and interpretation; Hammoud GM Corresponding author, edited and revised the manuscript.

**Correspondence to:** Ghassan M Hammoud, MD, MPH, Associate Professor of Clinical Medicine, Division of Gastroenterology and Hepatology, University of Missouri-Columbia, One Hospital Drive, CS and E Building, CE405, Columbia, MI 65212, United States. [hammoudg@health.missouri.edu](mailto:hammoudg@health.missouri.edu)

Telephone: +1-573-8828586 Fax: +1-573-8844595

Received: June 20, 2013 Revised: August 30, 2013

Accepted: September 3, 2013

Published online: October 15, 2013

### Abstract

Gangliocytic paraganglioma is a rare neuroendocrine tumor predominantly arising in the second part of the duodenum with rare local recurrence or metastasis to regional lymph nodes. A 92-year-old female presented with obstructive jaundice. On exam she had pale conjunctiva and icteric sclera. Abdominal examination revealed tenderness in the upper abdomen. Laboratory data was consistent with obstructive jaundice. Computed tomography of the abdomen revealed a dilated gall bladder and a common bile duct (CBD) with no evidence of liver lesions or pancreatic head mass. Endoscopic ultrasonography revealed a 1 cm isoechoic submucosal nodule at the periampullary area, dilated CBD (9 mm), a prominent pancreatic duct (4.1 mm) and a hydropic gall bladder with no stones. Endoscopic retrograde cholangiopancreatography was performed to relieve obstruction and showed a 1 cm periampullary mass which underwent an en-bloc snare resection. Histopathology

analyses with immunohistochemical stains were positive for cytokeratin, synaptophysin, S-100 protein, neuron specific enolase and negative for actin and desmin consistent with periampullary gangliocytic paraganglioma. Periampullary gangliocytic paraganglioma is a rare benign tumor of the small bowel. Common presentation includes abdominal pain and obstructive jaundice which should be included in differential diagnosis of obstructive jaundice. Endoscopic resection is a curative therapy in the absence of local invasion or distant metastasis.

© 2013 Baishideng. All rights reserved.

**Key words:** Gangliocytic paraganglioma; Periampullary tumor; Spindle-shaped; Epithelioid; Ganglion cells; Jaundice; Duodenum; Endoscopic mucosal resection


**Core tip:** This case report shed some light on a rare cause of obstructive jaundice in elderly patients. The disease is rare but should be considered in the differential diagnosis of biliary obstruction. The literature provided summarizes several outcomes of case presentation with this disorder and provide input on some of the aggressive feature of this disorder.

Sathyamurthy A, Choudhary A, Ng D, Okponobi S, Diaz-Arias A, Grewal A, Hammoud GM. Obstructive jaundice due to a rare periampullary tumor. *World J Gastrointest Oncol* 2013; 5(10): 195-197 Available from: URL: <http://www.wjgnet.com/1948-5204/full/v5/i10/195.htm> DOI: <http://dx.doi.org/10.4251/wjgo.v5.i10.195>


### INTRODUCTION

Gangliocytic paraganglioma is a rare neuroendocrine tumor predominantly arising in the second part of the duodenum with rare local recurrence or metastasis to regional lymph nodes. We present a case of a 92-year-old female with abdominal pain, obstructive jaundice and a mass in the second portion of the duodenum, near the papillary region.





**Figure 1** Endoscopic images of periampullary tumor prior and after endoscopic mucosal resection. A: A 1 cm × 1.5 cm isoechoic, submucosal nodule near the major ampulla (arrows); B: Periampullary submucosal nodule with a normal overlying mucosa; C: Lesion post endoscopic mucosal resection.



**Figure 2** Histologic characteristics of the gangliocytic paragangliomas. A: Submucosal location of the peri-ampullary tumor (H and E, original magnification × 2); Epithelioid cells (black arrow) with surrounding spindle cells (white arrow). Ganglion-like cells present (arrow heads) (H and E, original magnification × 20); B: Immunohistochemistry of tumor showing positivity for cytokeratin in the epithelioid cells (original magnification × 4); C: Immunohistochemistry of tumor showing S-100 positivity of the spindle cell component (original magnification × 10).

## CASE REPORT

A 92-year-old female presented with upper abdominal pain associated with nausea, vomiting and jaundice for 4 d. She had no history of fever, chills, melena, hematemesis or weight loss. Her past medical history was significant for diabetes, hypertension, gastroesophageal reflux, chronic renal insufficiency and hypothyroidism.

Physical examination revealed pale conjunctiva and icteric sclera with no cervical lymphadenopathy. Abdominal examination revealed tenderness in the upper abdomen with no rebound tenderness. She had no hepatosplenomegaly or palpable masses. Bowel sounds were present. Laboratory data were significant for hemoglobin 9.7 g/dL, total bilirubin 2.4 mg/dL, aspartate aminotransferase 166 U/L, alanine aminotransferase 465 U/L, and alkaline phosphatase 515 U/L. Her white cell count, serum amylase and lipase were normal. Computed tomography of abdomen revealed a dilated gallbladder and common bile duct (CBD = 9 mm) with no evidence of liver lesions or pancreatic head mass. Endoscopic ultrasound (EUS) revealed a well-defined, 1 cm × 1.5 cm heterogeneous, isoechoic, periampullary submucosal nodule (Figure 1A). The nodule appears to cause an extrinsic compression of the CBD at the ampullary orifice. The CBD was dilated at 10 mm in

diameter and the pancreatic duct (PD) appeared mildly prominent and measured 4.1 mm in diameter. The gallbladder appeared hydropic with no stones. The lesion did not appear to invade the CBD, PD or muscularis propria layer of the duodenal wall (Figure 1A). Endoscopic retrograde cholangiogram with biliary sphincterotomy was performed to relieve jaundice and showed a 1.5 cm × 2.0 cm periampullary nodule that partially obstruct the orifice of the major papilla (Figure 1B) which underwent en-bloc endoscopic mucosal resection with electrocautery snare (Figure 1C). Upon follow up, jaundice resolved once resection of the lesion was performed. There were no lymph nodes seen on EUS examination. Histopathology analyses with immunohistochemical stains were positive for cytokeratin (Figure 2B), synaptophysin, S-100 protein (Figure 2C), neuron specific enolase and negative for actin and desmin confirming the diagnosis of periampullary gangliocytic paraganglioma (Figure 2A). The margins were free of tumor and there were no histologic findings of aggressive behavior such as mitosis and/or pleomorphism.

## DISCUSSION

Gangliocytic paragangliomas are exceedingly rare tumors that arise in close proximity to the papilla of Vater and

**Table 1** Summary of case reports, findings and outcome from selected publications

Author	Presentation	Endoscopic findings	Outcome	Conclusion
Okubo <i>et al</i> <sup>[5]</sup>	56 yr old male with melena	EGD-tumor of ampulla of Vater with bleeding on surface	Pancreaticoduodenectomy	If followed up after a diagnosis, local excision can be curative, avoiding surgery or lymph node dissection
Witkiewicz <i>et al</i> <sup>[6]</sup>	61 yr old male with epigastric pain and melena	EGD, ERCP, EUS-tumor of papilla of Vater	Pylorus-preserving Pancreaticoduodenectomy and lymph node dissection; Lymph nodes positive	Do not limit to local resection, as disease recurrence, lymph node involvement or distant metastases may occur
Kwon <i>et al</i> <sup>[7]</sup>	38 yr old female with right upper quadrant abdominal pain	EGD-mass in duodenum near ampulla of Vater	Endoscopic excision of mass followed by pylorus-preserving pancreaticoduodenectomy as margin was positive	It may recur or metastasize; hence pancreaticoduodenectomy with lymph node dissection might be indicated for large lesions with infiltrative margin or lesions with pleomorphism and mitoses
Morita <i>et al</i> <sup>[8]</sup>	53 yr old male with incidental finding on EGD	EUS-submucosal tumor in the 3 <sup>rd</sup> -4 <sup>th</sup> layer	Endoscopic mucosal resection	Endoscopic removal is an alternative to surgical resection if no local or distant invasion
Sakhuja <i>et al</i> <sup>[9]</sup>	33 yr old male with obstructive jaundice	ERCP-periampullary growth	Pancreaticoduodenectomy	Recognize and diagnose this rare benign entity (with 3 components on H and E sections)
Evans <i>et al</i> <sup>[10]</sup>	56 yr old male with epigastric pain, vomiting and obstructive jaundice	EGD-pedunculated ampullary tumor	Pylorus-preserving total pancreatectomy	Benign entity-2 yr post procedure no recurrence of tumor

EGD: Esophagogastroduodenoscopy; ERCP: Endoscopic retrograde cholangiopancreatography; EUS: Endoscopic ultrasound.

90% are found in the second part of the duodenum<sup>[1]</sup>. The disease is common in the 5<sup>th</sup> decade and the incidence is slightly higher in males with M:F ratio 1.8:1. Gangliocytic paragangliomas are epithelial (submucosal) tumors with three histological cell types namely epithelioid, ganglion and spindle cells<sup>[2]</sup>.

Typical presentation is abdominal pain, gastrointestinal outlet obstruction and bleeding. However, obstructive jaundice is not common. In our case, jaundice was presumed secondary to mechanical obstruction of the ampullary orifice by the tumor. Immunohistochemistry is positive for cytokeratin, synaptophysin, neuron specific antigen and S-100 protein<sup>[2]</sup>. Endoscopic ultrasonography is useful for preoperative differential diagnosis such as gastrointestinal stromal tumors, carcinoids and periampullary adenoma. The disease generally follows a benign course with rare invasive growth patterns and lymph node metastasis<sup>[3,4]</sup>.

Histologic findings such as increase mitosis, pleomorphism, infiltrative margin and lymph node metastasis are suggestive of potential malignant features<sup>[5,6]</sup>. If feasible, endoscopic resection is a curative therapy in the absence of local invasion or distant metastasis. Table 1 shows summary of case reports, findings and outcome from selected publications<sup>[5-10]</sup>.

## REFERENCES

- 1 Scheithauer BW, Nora FE, LeChago J, Wick MR, Crawford BG, Weiland LH, Carney JA. Duodenal gangliocytic paraganglioma. Clinicopathologic and immunocytochemical study of 11 cases. *Am J Clin Pathol* 1986; **86**: 559-565 [PMID: 2877566]
- 2 Perrone T, Sibley RK, Rosai J. Duodenal gangliocytic paraganglioma. An immunohistochemical and ultrastructural study and a hypothesis concerning its origin. *Am J Surg Pathol* 1985; **9**: 31-41 [PMID: 2578747 DOI: 10.1097/0000478-198501000-00007]
- 3 Dookhan DB, Miettinen M, Finkel G, Gibas Z. Recurrent duodenal gangliocytic paraganglioma with lymph node metastases. *Histopathology* 1993; **22**: 399-401 [PMID: 8514287 DOI: 10.1111/j.1365-2559.1993.tb00145.x]
- 4 Hashimoto S, Kawasaki S, Matsuzawa K, Harada H, Makuuchi M. Gangliocytic paraganglioma of the papilla of Vater with regional lymph node metastasis. *Am J Gastroenterol* 1992; **87**: 1216-1218 [PMID: 1519587]
- 5 Okubo Y, Yokose T, Tuchiya M, Mituda A, Wakayama M, Hasegawa C, Sasai D, Nemoto T, Shibuya K. Duodenal gangliocytic paraganglioma showing lymph node metastasis: a rare case report. *Diagn Pathol* 2010; **5**: 27 [PMID: 20444291 DOI: 10.1186/1746-1596-5-27]
- 6 Witkiewicz A, Galler A, Yeo CJ, Gross SD. Gangliocytic paraganglioma: case report and review of the literature. *J Gastrointest Surg* 2007; **11**: 1351-1354 [PMID: 17653595 DOI: 10.1007/s11605-007-0217-9]
- 7 Kwon J, Lee SE, Kang MJ, Jang JY, Kim SW. A case of gangliocytic paraganglioma in the ampulla of Vater. *World J Surg Oncol* 2010; **8**: 42 [PMID: 20497533 DOI: 10.1186/1477-7819-8-42]
- 8 Morita T, Tamura S, Yokoyama Y, Onishi T, Kuratani Y, Mizuta H, Onishi S. Endoscopic resection of a duodenal gangliocytic paraganglioma. *Dig Dis Sci* 2007; **52**: 1400-1404 [PMID: 17415650 DOI: 10.1007/s10620-006-9370-3]
- 9 Sakhuja P, Malhotra V, Gondal R, Dutt N, Choudhary A. Periampullary gangliocytic paraganglioma. *J Clin Gastroenterol* 2001; **33**: 154-156 [PMID: 11468445 DOI: 10.1097/00004836-200108000-00013]
- 10 Evans JD, Wilson PG, Barber PC, Neoptolemos JP. Duodenal gangliocytic paraganglioma presenting as an ampullary tumor. *Int J Pancreatol* 1996; **20**: 131-134 [PMID: 8968869]

**P- Reviewers** El-Karakasy HM, Iacono C, Nakai Y  
**S- Editor** Wen LL **L- Editor** A **E- Editor** Liu XM





## GENERAL INFORMATION

*World Journal of Gastrointestinal Oncology* (*World J Gastrointest Oncol*, *WJGO*, online ISSN 1948-5204, DOI: 10.4251) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

### Aim and scope

*WJGO* covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, and therapy of benign and malignant tumors of the digestive tract. The current contents of *WJGO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

*WJGO* is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 42 OA clinical medical journals, including 41 in English, has a total of 15 471 editorial board members or peer reviewers, and is a world first-class publisher.

### Columns

The columns in the issues of *WJGO* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the fore-

front of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in gastrointestinal oncology; (12) Brief Articles: To briefly report the novel and innovative findings in gastrointestinal oncology; (13) Meta-Analysis: Covers the systematic review, mixed-treatment comparison, meta-regression, and overview of reviews, in order to summarize a given quantitative effect, e.g., the clinical effectiveness and safety of clinical treatments by combining data from two or more randomized controlled trials, thereby providing more precise and externally valid estimates than those which would stem from each individual dataset if analyzed separately from the others; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJGO*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of gastrointestinal oncology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

### Name of journal

*World Journal of Gastrointestinal Oncology*

### ISSN

ISSN 1948-5204 (online)



## Instructions to authors

### Launch date

October 15, 2009

### Frequency

Monthly

### Editorial-in-Chief

**Wasaburo Koizumi, MD, PhD, Professor, Chairman**, Department of Gastroenterology, Gastrointestinal Oncology, School of Medicine, Kitasato University, 2-1-1 Asamizodai Minamiku Sagamihara Kanagawa 252-0380, Japan

**Hsin-Chen Lee, PhD, Professor**, Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan

**Dimitrios H Roukos, MD, PhD, Professor**, Personalized Cancer Genomic Medicine, Human Cancer Biobank Center, Ioannina University, Metabatiko Ktirio Panepistimiou Ioanninon, Office 229, Ioannina, TK 45110, Greece

### Editorial Office

Jin-Lei Wang, Director

Xiu-Xia Song, Vice Director

*World Journal of Gastrointestinal Oncology*

Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China

Telephone: +86-10-59080039

Fax: +86-10-85381893

E-mail: [wjgo@wjgnet.com](mailto:wjgo@wjgnet.com)

<http://www.wjgnet.com>

### Publisher

Baishideng Publishing Group Co., Limited

Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road,  
Wanchai, Hong Kong, China

Telephone: +852-65557188

Fax: +852-31779906

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

### Production center

Beijing Baishideng BioMed Scientific Co., Limited

Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China

Telephone: +86-10-85381892

Fax: +86-10-85381893

### Representative office

USA Office

8226 Regency Drive,

Pleasanton, CA 94588-3144, United States

Telephone: +1-925-2238242

Fax: +1-925-2238243

### Instructions to authors

Full instructions are available online at [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312180518.htm](http://www.wjgnet.com/1948-5204/g_info_20100312180518.htm).

### Indexed and Abstracted in

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an ex-

pert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJGO* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book



Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

#### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/1948-5204/g\\_info\\_20100312180518.htm](http://www.wjgnet.com/1948-5204/g_info_20100312180518.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjgo@wjgnet.com](mailto:wjgo@wjgnet.com), or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

### MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

#### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. [montgomery.bissell@ucsf.edu](mailto:montgomery.bissell@ucsf.edu)

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381891 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

#### Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ), and CONCLUSION (no more than 26 words).

#### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

#### Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

#### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjgnet.com/1948-5204/g\\_info\\_list.htm](http://www.wjgnet.com/1948-5204/g_info_list.htm).

#### Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part

## Instructions to authors

should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...etc. It is our principle to publish high resolution-figures for the E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$  should be noted ( $P > 0.05$  should not be noted). If there are other series of  $P$  values, <sup>c</sup> $P < 0.05$  and <sup>d</sup> $P < 0.01$  are used. A third series of  $P$  values can be expressed as <sup>e</sup> $P < 0.05$  and <sup>f</sup> $P < 0.01$ . Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial let-

ter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

*English journal article (list all authors and include the PMID where applicable)*

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

*Chinese journal article (list all authors and include the PMID where applicable)*

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarrhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

*In press*

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

*Organization as author*

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 DOI:10.1161/01.HYP.0000035706.28494.09]

*Both personal authors and an organization as author*

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

*No author given*

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

*Volume with supplement*

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

*Issue with no volume*

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/0000-3086-200208000-00026]

*No volume or issue*

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

*Personal author(s)*

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

*Chapter in a book (list all authors)*

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

*Author(s) and editor(s)*

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiecezorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

*Conference proceedings*

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

*Conference paper*

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computa-

tional effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

#### Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

#### Patent (list all authors)

- 16 Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

#### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

#### Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as *v* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

#### Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6  $24.5 \mu\text{g/L}$ ; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312183048.htm](http://www.wjgnet.com/1948-5204/g_info_20100312183048.htm).

#### Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

#### Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindIII*, *BamHI*, *KhoI*, *KpnI*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

#### Examples for paper writing

All types of articles' writing style and requirement will be found in the

link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

## RESUBMISSION OF THE REVISED MANUSCRIPTS

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade B certificate (for non-native speakers of English), should be submitted to the online system via the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to [esps@wjgnet.com](mailto:esps@wjgnet.com).

#### Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

#### Copyright assignment form

Please download a Copyright assignment form from [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312182928.htm](http://www.wjgnet.com/1948-5204/g_info_20100312182928.htm).

#### Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/1948-5204/g\\_info\\_20100312182841.htm](http://www.wjgnet.com/1948-5204/g_info_20100312182841.htm).

#### Proof of financial support

For papers supported by a foundation, authors should provide a copy of the approval document and serial number of the foundation.

## STATEMENT ABOUT ANONYMOUS PUBLICATION OF THE PEER REVIEWERS' COMMENTS

In order to increase the quality of peer review, push authors to carefully revise their manuscripts based on the peer reviewers' comments, and promote academic interactions among peer reviewers, authors and readers, we decide to anonymously publish the reviewers' comments and author's responses at the same time the manuscript is published online.

## PUBLICATION FEE

WJGO is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. All invited articles are published free of charge.



百世登  
**Baishideng**®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

